Completed PHASE2 INTERVENTIONAL 1-arm NCT00349778

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Sponsor: Stanford University

Interventions Carmustine Cyclophosphamide Etoposide Filgrastim Melphalan

Updated 8 times since 2017 Last updated: Nov 8, 2017 Started: Aug 31, 2006 Primary completion: Apr 30, 2009 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00349778, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Stanford University, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2

Phase: PHASE1_PHASE2 → PHASE2
Jan 2017 — Dec 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States